ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Outcome measures"

  • Abstract Number: 0393 • ACR Convergence 2020

    Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS)

    Boyang Zheng1, Mianbo Wang2, Kerry McKenna3, Lee Shapiro4, Robert Spiera5, Richard Silver6, Mary Ellen Csuka7, Frank van den Hoogen8, David Robinson9, Laura Hummers10, Thomas Krieg11, Francesco Del Galdo12, Niall Jones13, Nader Khalidi14, Alessandra Vacca15, Jessica Gordon16, John Pauling17 and Murray Baron18, 1McGill University, Montreal, Canada, 2Lady Davis institute for Medical Research, Montreal, QC, Canada, 3Jewish General Hospital, McGill University, Montreal, Canada, 4Albany Medical College, Stillwater, NY, 5Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, 6Medical University of South Carolina, Charleston, 7Medical college of Wisconsin, Milwaukee, WI, 8Sint Maartenskliniek, Nijmegen, Netherlands, 9University of Manitoba, Winnipeg, MB, Canada, 10Johns Hopkins Univerisity, Ellicott City, MD, 11University of Cologne, Cologne, Germany, 12Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 13Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 14McMaster University, Hamilton, ON, Canada, 15University Hospital of Cagliari, Monserrato, Italy, 16Hospital for Special Surgery, New York, NY, 17Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 18Jewish General Hospital, Montreal, QC, Canada

    Background/Purpose: Diffuse cutaneous Systemic Sclerosis (dcSSc) is a morbid disease involving the skin and internal organs. The American College of Rheumatology has provisionally approved a…
  • Abstract Number: 0884 • ACR Convergence 2020

    Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

    Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Patrick Zueger4 and Alexis Ogdie5, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5University of Pennsylvania, Philadelphia, PA

    Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
  • Abstract Number: 1417 • ACR Convergence 2020

    Risk of Relapse of ANCA-associated Vasculitis in Patients of 75 Years and Older: A Retrospective Study

    Sara Thietart1, Guillaume Beinse2, Perrine Smets3, Alexandre Karras4, Carole Philipponnet5, Jean-François Augusto6, Khalil El Karoui7, Rafik Mesbah8, Dimitri Titeca Beauport9, Mohamed Hamidou10, Pierre-Louis Carron11, Julien Campagne12, Karim Sacre13, Pascal Cohen1, Eric Liozon14, Claire Blanchard-Delaunay15, Alex Kostianovsky16, Christian Pagnoux17, Luc Mouthon1, Loïc Guillevin18, Benjamin Terrier1 and Xavier Puéchal for the French Vasculitis Study Group1, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, 2Inserm UMR 1138, Centre de Recherche des Cordeliers, Paris, France, 3Department of Internal Medicine, Centre Hospitalier Universitaire Clermont-Ferrand Hôpital Gabriel-Montpied, Clermont Ferrand, France, 4Department of Nephrology, Hôpital Européen Georges Pompidou, Paris, France, 5Department of Nephrology, CHU Clermont-Ferrand, Clermont-Ferrand, Clermont Ferrand, France, 6Department of Nephrology-Dialysis-Transplantation, CHU Angers, Angers, France, 7Department of Nephrology and Transplantation, Hôpital Universitaire Henri-Mondor, Creteil, France, 8Department of Nephrology, CH Boulogne-sur-Mer, Boulogne-Sur-Mer, France, 9Department of Nephrology, Amiens University Medical Center, Amiens, France, 10Department of Internal Medicine, Hôtel-Dieu, CHU Nantes, Nantes, France, 11Department of Nephrology-Dialysis-Transplantation, CHU Grenoble-Alpes, Grenobles, France, 12Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France, 13Département de Médecine Interne, Hôpital Bichat, APHP, Paris, France, 14Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, 15Department of Internal Medicine, CH, Niort, France, 16Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno", Buenos Aeres, Argentina, 17Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 18Department of Internal Medecine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France

    Background/Purpose: ANCA-associated vasculitis (AAV) frequently occurs among older patients, with different clinical presentations than the younger. Little is known on the outcome of older patients…
  • Abstract Number: 1725 • ACR Convergence 2020

    An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice

    Elston He1, Pratyusha Yalamanchi2, William Arnold3 and Erin Arnold4, 1Synovium, Inc., Philadelphia, PA, 2Michigan Medicine, Ann Arbor, MI, 3Retired, Wilmette, IL, 4Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL

    Background/Purpose: Disease presentation and progression in rheumatoid arthritis (RA) is highly heterogeneous and requires careful consideration of outcome measurements to be used for individual patients.…
  • Abstract Number: 2007 • ACR Convergence 2020

    Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-Severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate

    Peter Taylor1, Bryan Downie2, Emon Elboudwarej2, Sam Kim2, Angie Hertz2, Amer Mirza2, Jeff Siegel3, Rachael Hawtin2 and Jinfeng Liu2, 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster City, 3Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA).…
  • Abstract Number: 0247 • ACR Convergence 2020

    Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus

    Ji-Won Kim1, Ju-Yang Jung1, Hyoun-Ah Kim1 and Chang-Hee Suh1, 1Ajou university school of medicine, Suwon, Republic of Korea

    Background/Purpose: This study aimed to examine the frequency and risk factors of complications during pregnancy in women with systemic lupus erythematosus (SLE).Methods: The medical records…
  • Abstract Number: 0427 • ACR Convergence 2020

    Validation of Physician Global Assessment as an Outcome Measure in Relapsing Polychondritis

    Emily Rose1, Marcela Ferrada1, Kaitlin Quinn2, Wendy Goodspeed1, Laurent Arnaud3 and Peter C. Grayson4, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, BETHESDA, MD, 2Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 3Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, Alsace, France, 4Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

    Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disorder of cartilage that lacks validated disease activity measures. Physician global assessment (PhGA) is a measure…
  • Abstract Number: 0886 • ACR Convergence 2020

    Achievement of Partial Remission and Inactive Disease in Upadacitinib-Treated Patients with Ankylosing Spondylitis

    Atul Deodhar1, Andrew Östör2, Anna Maniccia3, Fabiana Ganz4, Tianming Gao3, Alvina D. Chu5 and Denis Poddubnyy6, 1Oregon Health & Science University, Portland, OR, 2Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, 3AbbVie Inc., North Chicago, IL, 4AbbVie Inc., Baar, Switzerland, 5AbbVie, North Chicago, IL, 6Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) response criteria and AS Disease Activity Score (ASDAS) are both commonly used, rigorous composite indices consisting of components…
  • Abstract Number: 1457 • ACR Convergence 2020

    Two Minute Walking Distance and Other Timed Function Tests Are Superior to MMT-8 in Assessing Outcomes in Polymyositis and Dermatomyositis

    Sai kumar Dunga1, Chengappa G Kavadichanda2 and VS Negi2, 1Jawaharlal institute of postgraduate medical education and research, puducherry, India, 2Jawaharlal institute of postgraduate medical education and research, Puducherry, Puducherry, India

    Background/Purpose: Inflammatory myositis are heterogenous group of diseases affecting skeletal muscles and multiple different organs. Assessing improvement in disease activity is done by Manual muscle…
  • Abstract Number: 1726 • ACR Convergence 2020

    Assessment of the Components of RAPID3 Patient Reported Outcomes in an Community Rheumatology Practice

    Elston He1, Pratyusha Yalamanchi2, William Arnold3 and Erin Arnold4, 1Synovium, Inc., Philadelphia, PA, 2Michigan Medicine, Ann Arbor, MI, 3Retired, Wilmette, IL, 4Private Practice, Orthopaedics and Rheumatology of the North Shore, Wilmette, IL

    Background/Purpose: Patient reported outcomes are integral to measuring patient response to treatment for rheumatoid arthritis (RA). RAPID3 is a patient reported outcome metric that consists…
  • Abstract Number: 2013 • ACR Convergence 2020

    Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort

    Sjef van der Linden1, Peter Villiger2, Zhixiu Li3, Matthew Brown4, Heinz Baumberger5, Hermine Zandwijk6 and Muhammad Khan7, 1Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, 2Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, 3Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, 4Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, 5Retired, Flims, Tajikistan, 6Retired, Mortroux, Belgium, 7Case Western Reserve University, Cleveland OH, Westlake, OH

    Background/Purpose: Familial occurrence of ankylosing spondylitis (AS) is well known. Our follow-up study aimed at assessing the incidence of clinically defined AS among first degree…
  • Abstract Number: 0250 • ACR Convergence 2020

    Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience

    Andrea Fava1, Jessica Li1, Philip Carlucci2, David Wofsy3, Judith James4, Chaim Putterman5, Betty Diamond6, Derek Fine7, Jose Monroy-Trujillo7, Kristin Haag7, Kristina Deonaraine8, The Accelerating Medicines Partnership in SLE Network9, William Apruzzese10, Jill Buyon11 and Michelle Petri12, 1Johns Hopkins University, Baltimore, MD, 2New York University School of Medicine, New York, NY, 3University of California San Francisco, San Francisco, CA, 4Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK, 5Albert Einstein College of Medicine, Bronx, NY, 6Northwell Health, Manhasset, NY, 7Johns Hopkins University, Baltimore, 8New York University School of Medicine, New York, 9Multiple Institutions, Multiple Cities, 10., Boston, 11Department of Medicine, NYU School of Medicine, New York, NY, 12Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: The Accelerating Medicines Partnership (AMP) will use multi-omics modalities including single cell RNA sequencing to understand lupus nephritis with the ultimate goal to devise…
  • Abstract Number: 0482 • ACR Convergence 2020

    Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort

    Edward C Keystone1, Mohammad Movahedi2, Angela Cesta3, Claire Bombardier4, John Sampalis5 and Emmanouil Rampakakis5, 1Mount Sinai Hospital, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3Toronto General Hospital Research Institute, Toronto, ON, Canada, 4Institute for Work and Health, Toronto, ON, Canada, 5JSS Medical Research, St-Laurent, QC, Canada

    Background/Purpose: Treat-to-target recommendations for rheumatoid arthritis (RA) dictate that remission or low disease activity should be aimed. Although numerous composite indices are available, the clinical…
  • Abstract Number: 0896 • ACR Convergence 2020

    Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs

    Iain McInnes1, William Tillett2, Philip Mease3, Kurt de Vlam4, Louis Bessette5, Ralph Lippe6, Anna Maniccia7, Patrick Zueger7, Dai Feng7, Koji Kato8 and Andrew Östör9, 1Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, 3Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 4Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 5Laval University, Quebec, Canada, 6AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 7AbbVie Inc., North Chicago, IL, 8AbbVie Inc, North Chicago, IL, 9Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Pain is a dominant symptom of psoriatic arthritis (PsA), and pain reduction is a priority for patients (pts) that is often assessed in clinical…
  • Abstract Number: 1490 • ACR Convergence 2020

    Pain Rating Variability and Response to Treatment in Osteoarthritis Clinical Trials

    Camila Pinto1, Joana Barroso2 and Thomas Schnitzer3, 1Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, 3Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Despite the known high inter- and intra-patient variability in analgesic responses in chronic pain, most interventional pain studies rely on single time point pain…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology